A5072749229- Systemic Lupus Erythematosus Research
- COVID-19 Clinical Research Studies
- Acute Kidney Injury Research
- Muscle and Compartmental Disorders
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Long-Term Effects of COVID-19
- Parvovirus B19 Infection Studies
- Immune Cell Function and Interaction
- Pregnancy and preeclampsia studies
- Gastrointestinal Bleeding Diagnosis and Treatment
- Trauma and Emergency Care Studies
- Rheumatoid Arthritis Research and Therapies
- Otitis Media and Relapsing Polychondritis
- Vasculitis and related conditions
- Drug-Induced Adverse Reactions
- Bone and Joint Diseases
- Spondyloarthritis Studies and Treatments
- SARS-CoV-2 and COVID-19 Research
- Sarcoidosis and Beryllium Toxicity Research
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Systemic Sclerosis and Related Diseases
- Autoimmune and Inflammatory Disorders Research
- Autopsy Techniques and Outcomes
King's College Hospital
2023-2024
King's College Hospital NHS Foundation Trust
2020-2023
Queen Elizabeth Hospital
2021
Abstract Background Acute kidney injury (AKI) is common among patients hospitalised with COVID-19 and associated worse prognosis. The aim of this study was to investigate the epidemiology, risk factors outcomes AKI in a large UK tertiary centre. Methods We analysed data consecutive adults admitted laboratory-confirmed diagnosis across two sites hospital London, UK, from 1st January 13th May 2020. Results Of 1248 inpatients included, 487 (39%) experienced (51% stage 1, 13% 2, 36% 3). weekly...
Abstract Objectives The National Health Service in England funds 12 months of weekly s.c. tocilizumab (qwTCZ) for patients with relapsing or refractory GCA. During the coronavirus disease 2019 (COVID-19) pandemic, some were allowed longer treatment. We sought to describe what happened after cessation qwTCZ. Methods Multicentre service evaluation relapse stopping qwTCZ log-rank test was used identify significant differences time relapse. Results A total 336 GCA analysed from 40 centres,...
<h3>Background:</h3> SLE is marked by immune dysregulation linked to pathogenesis, clinical disease activity, and flare. Capturing prior flare onset may provide a window for early intervention decrease frequency severity. <h3>Objectives:</h3> This study seeks validate recently refined Lupus Flare Risk Index (L-FRI)[<i>1</i>] that reflects altered immunity using unique confirmatory cohort of patients. <h3>Methods:</h3> The L-FRI the sum log-transformed, standardized mediators, weighted...
Haemophagocytic lymphohistiocytosis is a severe systemic hyperinflammatory syndrome characterised by dysregulation of immune cells and excessive production cytokines, also known as cytokine storm. It has distinctive clinical features with fever, hyperferritinaemia falling blood counts. In adults, this usually occurs secondary to an underlying driver or trigger including infection, malignancy rheumatic diseases. Prompt treatment immunomodulatory therapy, corticosteroids the recombinant IL-1...
<h3>Objective</h3> Globally, there is an absence of standardised protocols for the treatment SLE. This study aimed to conduct a worldwide evaluation treatment, including use steroids, conventional DMARDs and biologic agents in Additionally, we sought explore impact Human Development Index (HDI) on regional variations therapy. <h3>Methods</h3> Data from COVID-19 database patient demographics treatments was grouped by continent. collection included current including; corticosteroids (CS),...
<h3>Objective</h3> This study aimed to investigate the prevalence of comorbidity, multimorbidity and mental health disorders in patients with systemic lupus erythematous (SLE) association patient reported physical outcome scores (PROMIS). <h3>Methods</h3> Data from COVAD survey was utilised for analysis. Comorbidities including cardiovascular disease (ischaemic heart disease, hypertension, hypercholesterolaemia), diabetes, respiratory (interstitial lung chronic obstructive pulmonary...
<h3>Background:</h3> Systemic lupus erythematosus (SLE) is a chronic autoimmune disease underscored by complex immune dysregulation, including altered mediators and accumulation of autoantibody (AutoAb) specificities. Such dysregulation drives the pathogenesis SLE; patients experience varied activity that must be managed to prevent end organ damage leads morbidity early mortality. With current shortage rheumatologists administrative burden validated clinical measures, capturing such...
Abstract Introduction Difficult-to-treat rheumatoid arthritis (D2T RA) remains an area of unmet need in rheumatology. Despite the increasing availability biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) choices to treat RA, a significant proportion patients with D2T RA still fail achieve low disease activity or remission [1]. Here we present case patient refractory multiple lines conventional DMARDs (cDMARDs) biological (bDMARDs), who has been managed novel...
Abstract Background : Acute kidney injury (AKI) is common among patients hospitalised with COVID-19, and associated worse prognosis. The aim of this study was to investigate the epidemiology, risk factors outcomes AKI in COVID-19 a large UK tertiary centre. Methods: We analysed data consecutive adults admitted laboratory-confirmed diagnosis across two sites hospital London, UK, from 1st January 13th May 2020. Results Of 1248 inpatients included, 487 (39%) experienced (51% stage 1, 13% 2,and...
Abstract Case report - Introduction Golimumab is an anti-TNF alpha drug used in the treatment of inflammatory arthritis including spondyloarthritis (SpA). The introduction this class has revolutionised SpA over last 20 years with significantly improved patient outcomes. Despite their benefits multiple adverse effects TNF-alpha inhibition have been reported through clinical trials a possible increased risk malignancy. We describe case known ankylosing spondylitis (AS) on golimumab who was...
<h3>Background</h3> Systemic lupus erythematosus (SLE) can result in impaired daily physical function through various mechanisms including active disease, chronic damage, and mental health symptoms that are common the disease. However, key drivers of reduced poorly understood, no large-scale global studies investigating this have been conducted to date. <h3>Objectives</h3> To investigate factors contribute SLE globally. <h3>Methods</h3> patients were identified from COVAD 2 database, a...
<h3>Background</h3> Regional disparities in the management of systemic lupus erythematosus (SLE) are frequently described. Governance, funding, logistic barriers, and physician choice may be important determinants though scarce data from underrepresented regions limits our understanding. <h3>Objectives</h3> To evaluate global patterns treatment SLE identify prevalence comorbidities. <h3>Methods</h3> We identified patients COVAD 2 database, consisting over 20,000 respondents worldwide....
Acute kidney injury (AKI) is a common complex condition associated with substantial morbidity, mortality and cost (NHS £1.02 billion per year for AKI related inpatient care). In 2013 NHS England in partnership the UK Renal Registry, launched National Prevention Programme aim of improving care patients recommended implementing patient safety alerts. Clinical Nurse Specialists (AKI CNS) may provide novel opportunity to improve outcomes but there limited understanding impact their role. The...